IGM Biosciences Inc - ESG Rating & Company Profile powered by AI
This ESG score for IGM Biosciences Inc represents the company's transparency towards the UN SDGs. This analysis of IGM Biosciences Inc uses information from across the internet as well as from public disclosures by IGM Biosciences Inc. If you are employed by IGM Biosciences Inc and you would like to licence your Sustainability aseessment, please get in touch.
IGM Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 4.6, social score of 4.0 and governance score of 5.0.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1156 | Vectus Biosystems Ltd | 4.7 | High |
| 1156 | Zynerba Pharmaceuticals Inc | 4.7 | High |
| 1199 | IGM Biosciences Inc | 4.6 | High |
| 1199 | Allergan Inc | 4.6 | High |
| 1199 | AroCell AB (publ) | 4.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does IGM Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes IGM Biosciences Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes IGM Biosciences Inc report the average age of the workforce?
Sign up for free to unlockDoes IGM Biosciences Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes IGM Biosciences Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes IGM Biosciences Inc disclose cybersecurity risks?
Sign up for free to unlockDoes IGM Biosciences Inc offer flexible work?
Sign up for free to unlockDoes IGM Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes IGM Biosciences Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes IGM Biosciences Inc conduct supply chain audits?
Sign up for free to unlockDoes IGM Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes IGM Biosciences Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes IGM Biosciences Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes IGM Biosciences Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes IGM Biosciences Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes IGM Biosciences Inc disclose water use targets?
Sign up for free to unlockDoes IGM Biosciences Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid IGM Biosciences Inc have a product recall in the last two years?
Sign up for free to unlockDoes IGM Biosciences Inc disclose incidents of discrimination?
Sign up for free to unlockDoes IGM Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas IGM Biosciences Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes IGM Biosciences Inc disclose parental leave metrics?
Sign up for free to unlockDoes IGM Biosciences Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes IGM Biosciences Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes IGM Biosciences Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes IGM Biosciences Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes IGM Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes IGM Biosciences Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs IGM Biosciences Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes IGM Biosciences Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes IGM Biosciences Inc disclose its waste policy?
Sign up for free to unlockDoes IGM Biosciences Inc report according to TCFD requirements?
Sign up for free to unlockDoes IGM Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes IGM Biosciences Inc disclose energy use targets?
Sign up for free to unlockDoes IGM Biosciences Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes IGM Biosciences Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for IGM Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.